{"id":293,"date":"2024-06-08T13:30:18","date_gmt":"2024-06-08T13:30:18","guid":{"rendered":"https:\/\/dev.campbellneurosciences.com\/?page_id=293"},"modified":"2024-06-08T13:30:18","modified_gmt":"2024-06-08T13:30:18","slug":"therapeutic-solutions-international-launches-clinical-trial-to-validate-first-blood-based-predicator-of-suicidal-ideation-the-campbell-score","status":"publish","type":"page","link":"https:\/\/campbellneurosciences.com\/index.php\/therapeutic-solutions-international-launches-clinical-trial-to-validate-first-blood-based-predicator-of-suicidal-ideation-the-campbell-score\/","title":{"rendered":"Therapeutic Solutions International Launches Clinical Trial to Validate First Blood Based Predicator of Suicidal Ideation: The Campbell Score\u2122"},"content":{"rendered":"

[et_pb_section fb_built=”1″ custom_padding_last_edited=”on|tablet” next_background_color=”#ffffff” admin_label=”Hero” _builder_version=”4.24.3″ use_background_color_gradient=”on” background_color_gradient_type=”circular” background_color_gradient_direction_radial=”top right” background_color_gradient_stops=”rgba(255,255,255,0) 20%|rgba(1,77,183,0.9) 100%” background_color_gradient_overlays_image=”on” background_color_gradient_start=”rgba(255,255,255,0)” background_color_gradient_start_position=”20%” background_color_gradient_end=”rgba(1,77,183,0.9)” background_image=”https:\/\/campbellneurosciences.com\/wp-content\/uploads\/2024\/06\/shutterstock_1028494843-scaled.jpg” custom_padding=”110px|0px|49px|0px|false|false” custom_padding_tablet=”50px||50px||true” custom_padding_phone=”|||” bottom_divider_style=”asymmetric” bottom_divider_height=”50px” bottom_divider_flip=”horizontal” bottom_divider_height_tablet=”90px” bottom_divider_height_phone=”80px” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row column_structure=”2_3,1_3″ _builder_version=”4.16″ custom_width_px=”1280px” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”2_3″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text _builder_version=”4.24.3″ text_font=”Montserrat||||||||” text_text_color=”rgba(255,255,255,0.7)” text_font_size=”20px” text_line_height=”1.8em” header_font=”Montserrat|700|||||||” header_font_size=”44px” header_line_height=”1.4em” header_6_font=”Montserrat|600||on|||||” header_6_text_color=”rgba(255,255,255,0.7)” header_6_font_size=”16px” header_6_letter_spacing=”2px” header_6_line_height=”1.5em” background_layout=”dark” max_width=”780px” custom_margin=”-65px|||||” text_font_size_tablet=”” text_font_size_phone=”15px” text_font_size_last_edited=”on|phone” header_font_size_tablet=”” header_font_size_phone=”28px” header_font_size_last_edited=”on|phone” global_colors_info=”{}” theme_builder_area=”post_content”]<\/p>\n

Campbell Neurosciences, inc.<\/span><\/h1>\n

Committed to establishing a biological basis for diagnosis and treatment of suicide and its causes, including Schizophrenia and other mental health disorders, thereby eliminating the stigma of the disease.<\/span><\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.24.3″ _module_preset=”default” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row _builder_version=”4.24.3″ _module_preset=”default” custom_margin=”-31px|auto||auto||” custom_padding=”0px|||||” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.24.3″ _module_preset=”default” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_text _builder_version=”4.24.3″ _module_preset=”default” global_colors_info=”{}” theme_builder_area=”post_content”]<\/p>\n

\n

Therapeutic Solutions International Launches Clinical Trial to Validate First Blood Based Predicator of Suicidal Ideation: The Campbell Score\u2122<\/strong><\/span><\/h2>\n

Clinical Stage Biotech Company Aims to Develop Biology Based Means of Assessing Suicide Risk and Providing Immunotherapy Based Interventions<\/em><\/span><\/p>\n

\n

The Campbell Score\u2122, which is a patent-pending method of quantifying inflammatory-associated biological markers, has previously been shown in pilot investigator-initiated studies to correlate with propensity for suicide. Based on positive feedback from collaborators, the Company decided to initiate a formal clinical trial to validate correlations between the Campbell Score\u2122 and established psychiatric assessment tools of suicidal propensity.\u00a0\u00a0<\/span>Currently the only means of quantifying predisposition to suicide is based on psychological, question-based techniques.\u00a0\u00a0<\/span>These tests are highly subjective and biased based on desire of questionee to avoid being labeled as \u201ccrazy\u201d.<\/p>\n

\u201cI am thankful for Timothy Dixon and the team at TSOI for working to establish a biological basis of suicide as a disease and not a choice\u201d said Kalina O\u2019Connor, Director of the Campbell Neurosciences Division of the Company. \u201cRigorous scientific validation of the Campbell Score\u2122, will be the first step in establishing a foundation for a paradigm shift in the way that suicide is approached.\u201d<\/p>\n

Therapeutic Solutions International has previously filed patents for diagnosing people at high risk of suicide and intervening using immunotherapy and stem cell based approaches.<\/p>\n

\u201cAccording to the World Health Organization, suicide is the #2 cause of death for people between the ages of 15 and 292<\/sup>\u201d said Famela Ramos, Director of Business Development of the Company. \u201cI am honored to be involved with a company that not only is working on developing the first objective means of quantifying suicidal thoughts, but also is the first to believe that taking one\u2019s life occurs because of a biochemical abnormality and not \u201ctaking the easy way out\u201d.<\/p>\n

\u201cThe Campbell Score\u2122 is named after Kathleen Campbell, the mother of Kalina O\u2019Connor who was victim of suicide.\u00a0\u00a0<\/span>We strive in her name, and the name of the multiple victims of suicide, to lay down the scientific basis, and intellectual property foundation, for repositioning suicide from a stigma to a bona fide medical condition\u201d said Timothy Dixon, President and CEO of Therapeutic Solutions International.\u00a0<\/span>\u00a0\u00a0<\/span><\/p>\n

About Therapeutic Solutions International, Inc.<\/strong>
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company\u2019s corporate website is www.therapeuticsolutionsint.com, and our public forum is https:\/\/board.therapeuticsolutionsint.com\/and Campbell Neurosciences at https:\/\/www.campbellneurosciences.com<\/p>\n

[1]<\/span>\u00a0<\/span>https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04606875<\/p>\n

2<\/span>\u00a0<\/span>https:\/\/www.who.int\/mental_health\/prevention\/suicide\/suicideprevent\/en\/<\/p>\n

 <\/p>\n

 <\/p>\n<\/header>\n

\n
<\/div>\n<\/div>\n
\n
\n

 <\/p>\n<\/div>\n<\/div>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

Campbell Neurosciences, inc. Committed to establishing a biological basis for diagnosis and treatment of suicide and its causes, including Schizophrenia and other mental health disorders, thereby eliminating the stigma of the disease. Therapeutic Solutions International Launches Clinical Trial to Validate First Blood Based Predicator of Suicidal Ideation: The Campbell Score\u2122 Clinical Stage Biotech Company Aims […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-293","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/campbellneurosciences.com\/index.php\/wp-json\/wp\/v2\/pages\/293","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/campbellneurosciences.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/campbellneurosciences.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/campbellneurosciences.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/campbellneurosciences.com\/index.php\/wp-json\/wp\/v2\/comments?post=293"}],"version-history":[{"count":2,"href":"https:\/\/campbellneurosciences.com\/index.php\/wp-json\/wp\/v2\/pages\/293\/revisions"}],"predecessor-version":[{"id":296,"href":"https:\/\/campbellneurosciences.com\/index.php\/wp-json\/wp\/v2\/pages\/293\/revisions\/296"}],"wp:attachment":[{"href":"https:\/\/campbellneurosciences.com\/index.php\/wp-json\/wp\/v2\/media?parent=293"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}